VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy Virtual 2020 | Novel drugs for myeloma thromboprophylaxis

Heinz Ludwig • 13 May 2020
COMy Virtual 2020
Multiple Myeloma Apixaban Edoxaban

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, talks on myeloma thromboprophylaxis, specifically, the use of novel anticoagulants such as edoxaban and apixaban. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Heinz Ludwig

1:45
Latest updates on maintenance therapy in myeloma
Heinz Ludwig • 1 Jun 2021
5:59
Novel models of interaction between patients and HCPs
Heinz Ludwig • 8 Mar 2021
3:32
Evaluating serum free light chain ratio as a biomarker for progression to multiple myeloma
Heinz Ludwig • 8 Jun 2022
1:40
Maximizing supportive care
Heinz Ludwig • 12 May 2020

Related Videos

4:28
A.R.R.O.W. study: carfilzomib dosing in frail MM patients
Maria-Victoria Mateos
1:16
Managing CRS in myeloma
Nina Shah
2:26
Managing transplant patients during the COVID-19 pandemic
Christian Chabannon
3:43
DNA methyltransferase inhibitors: daratumumab enhancement for MM
Priya Choudhry
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals